Mikio Yanase

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 466 citations

Medicine, Internal Medicine, Pharmacotherapy +12

Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial

Masashi Mizokami, Osamu Yokosuka, Tetsuo Takehara et al. · The Lancet Infectious Diseases · 2015 · 362 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +13

Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 <scp>HCV</scp> infection: an open‐label, phase 3 trial

Masao Omata, Shuhei Nishiguchi, Yoshiyuki Ueno et al. · Journal of Viral Hepatitis · 2014 · 202 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Both Plasma Lysophosphatidic Acid and Serum Autotaxin Levels are Increased in Chronic Hepatitis C

Naoko Watanabe, Hitoshi Ikeda, Kazuhiro Nakamura et al. · Journal of Clinical Gastroenterology · 2007 · 191 citations

Life Sciences, Biochemistry, Pathology +13

Development and Validation of a Risk Scoring System for Severe Acute Lower Gastrointestinal Bleeding

Tomonori Aoki, Naoyoshi Nagata, Takuro Shimbo et al. · Clinical Gastroenterology and Hepatology · 2016 · 134 citations

Medicine, Emergency Medicine, Clinical Classification Systems +10